Primary Care Clinics in Somersworth, NH Accepting Medicare
6 Primary Care Clinics found. Showing 1 - 6
 Greater Seacoast Community Health Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 11 Memorial Dr, Somersworth, NH 03878 Phone: 603-749-2346 Fax: 603-953-0066 |
Atlantic Digestive Specialists, Pllc Internal Medicine - Gastroenterology Medicare: Medicare Enrolled Practice Location: 21 Clark Way, Somersworth, NH 03878 Phone: 603-692-2228 Fax: 603-692-0418 |
Seacoast Orthopedics & Sports Medicine, Pa Family Medicine - Sports Medicine Medicare: Medicare Enrolled Practice Location: 7 Marsh Brook Dr, Suite 100, Somersworth, NH 03878 Phone: 603-742-2007 Fax: 603-749-4605 |
Donna M. Fredette Dba Tri City Counseling Clinic/Center - Multi-Specialty Medicare: Not Enrolled in Medicare Practice Location: 150 West High St, Somersworth, NH 03878 Phone: 603-661-7403 |
Goodwin Community Health Clinic/Center - Community Health Medicare: Not Enrolled in Medicare Practice Location: 311 Route 108, Somersworth, NH 03878 Phone: 603-749-2346 Fax: 603-953-0066 |
Avis Goodwin Community Health Center Clinic/Center - Community Health Medicare: Not Enrolled in Medicare Practice Location: 311 Route 108, Somersworth, NH 03878 Phone: 603-749-2346 Fax: 603-953-0066 |
News Archive
Lopinavir and ritonavir drug combo tested in severe COVID-19
Researchers from China and the United Kingdom have collaborated to conduct a clinical trial looking at the efficacy of a combination of two anti-HIV drugs lopinavir and ritonavir to combat severe cases of COVID-19. Their study titled, "A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19," was published in the latest issue of the New England Journal of Medicine (NEJM).
StemCyte receives two cash grants under QTDP program for biomedical research
StemCyte, Inc., one of the world's preeminent umbilical cord blood (UCB) banks and biotherapy companies, is proud to announce that the Company has been awarded two cash grants totaling $488,950 under the U.S. Internal Revenue Service's Qualifying Therapeutic Discovery Project (QTDP) program designed to support biomedical research by firms with fewer than 250 employees.
Scientists identify biological mechanism that may be responsible for icy extremities
Cold feet-those chilly appendages that plague many people in the winter and an unlucky few all year round-can be the bane of existence for singles and couples alike. In a new study, scientists led by Selvi C. Jeyaraj of the Research Institute at Nationwide Children's Hospital have identified a biological mechanism that may be responsible for icy extremities: an interaction between a series of molecules and receptors on smooth muscle cells that line the skin's tiny blood vessels.
Activated astrocytes could play a harmful role in Alzheimer's disease
A research team composed of University of Kentucky researchers has published a paper which provides the first direct evidence that activated astrocytes could play a harmful role in Alzheimer's disease.
JCOM receives approval from KFDA to commercialize MuGard in Korea
ACCESS PHARMACEUTICALS, INC. announced that JCOM Co., Ltd., its Korean licensee for both MuGard™ and ProLindac™, has received approval from the Korean Food and Drug Administration of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis.
› Verified 2 days ago